August issue of Journal of Cardiac Failure (JCF) features updated national guidance alongside a dynamic collection of original research, reviews, and perspectives advancing heart failure care
WASHINGTON, DC (August 12, 2025) – A newly updated Guideline on the Diagnosis and Treatment of Heart Failure—developed jointly by the Japanese Circulation Society (JCS) and the Japanese Heart Failure Society (JHFS)—has been published in JCF, the official journal of the Heart Failure Society of America (HFSA). This update provides a comprehensive, evidence-based framework for the management of heart failure across a spectrum of patient populations and disease presentations and reflects recent advancements in international heart failure care.
The updated guideline incorporates key recommendations for guideline-directed medical therapy (GDMT), including:
- Sodium–glucose cotransporter 2 (SGLT2) inhibitors and the mineralocorticoid receptor antagonist finerenone for patients with heart failure with mildly reduced (HFmrEF) and preserved ejection fraction (HFpEF)
- Incretin-based therapies for heart failure patients with comorbid obesity
- Mavacamten for the treatment of hypertrophic cardiomyopathy
- Vutrisiran and acoramidis for transthyretin amyloid cardiomyopathy
In addition to these pharmacologic advances, the guideline introduces new sections addressing complex and emerging clinical challenges, such as atrial cardiomyopathy, triglyceride deposit cardiomyovasculopathy, cardiovascular issues in geriatric and frail populations, and cardio-oncology considerations.
“This important update integrates the latest global consensus and evidence, while also addressing the distinct needs of heart failure care in Japan’s aging population and within the context of its universal healthcare system,” said JCF co-editors-in-chief Robert J. Mentz, MD and Anuradha Lala, MD. “We’re proud to feature this important work in our August issue—an edition that also showcases a dynamic range of science and perspectives advancing the field of heart failure. From cutting-edge therapeutics to multidisciplinary care insights, it’s a must-read for clinicians and researchers alike.”
For additional commentary on the new guideline, a Perspectives piece Insights From Around the World: the 2025 Japanese Heart Failure Guidelines is also available online.
The full line-up for the JCF September issue is as follows:
Original Research Papers
- Post-Discharge Self-Care Confidence and Performance Levels in Patients Hospitalized due to Heart Failure
- Editorial: Back to Basics: Self-Care Education to Empower Patients with Heart Failure
- Prognostic Impact of Thyroid Function in Patients With Incident Heart Failure: A Nationwide Study
- Effectiveness of Virtual Care Team Guided Management of Hospitalized Patients with HFrEF by Ethnicity
- Editorial: Placing Attention on Behaviors to Reduce Disparities in Heart Failure Care
- Performance of Clinical Scoring Systems in the Diagnosis of Transthyretin Amyloid Cardiomyopathy in a Diverse Patient Cohort
- Editorial: Improving ATTR-CM Detection: Targeting Populations With the Greatest Need
- Right Ventricular Mass Oversizing Is Associated With Improved Post-transplant Survival in Heart Transplant Recipients With Elevated Transpulmonary Gradient
- Clinical Practice Guideline: JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Paired Perspective
State-of-the-Art Review
Perspectives
Brief Reports
- Real-World Analysis of Health Care Utilization With Baroreflex Activation Therapy for Heart Failure
- Acoramidis for Transthyretin Amyloid Cardiomyopathy: Open-Label Extension Study Long-Term Follow-Up
- NSAIDs Use, Kidney Outcomes and the Effect of Empagliflozin: An Analysis from EMPEROR-Preserved
- Cardiologist-Reported Reasons for Not Titrating Guideline-Directed Medical Therapy for Heart Failure with Reduced Ejection Fraction
Research Letter
View the full issue online. For interviews with authors, please contact Laura Poko at lpoko@hfsa.org.
About the Journal of Cardiac Failure
The Journal of Cardiac Failure (JCF) publishes the highest quality science in the field of heart failure with a focus on diversity, equity, and inclusion, mentorship, multidisciplinary partnerships, and patient-centeredness. Published papers span original investigator-initiated work to state-of-the-art reviews, guidelines and scientific statements, expert perspectives, early career and trainee spotlight pieces, patient and patient-partner narratives. JCF also emphasizes the power of language and prioritizes innovative approaches to dissemination of published work to reach and impact the broader heart failure community.
About the Heart Failure Society of America
The Heart Failure Society of America, Inc. (HFSA) represents the first organized effort by heart failure experts from the Americas to provide a forum for all those interested in heart function, heart failure, and congestive heart failure (CHF) research and patient care. The mission of HFSA is to provide a platform to improve and expand heart failure care through collaboration, education, innovation, research, and advocacy. HFSA members include physicians, scientists, nurses, nurse practitioners, pharmacists, trainees, other healthcare workers and patients. For more information, visit hfsa.org.
Media Contact: Laura Poko, 301-798-4493, ext. 226, lpoko@hfsa.org